PeerJ

NAT10 may block cell death and help kidney cancer grow by controlling the NFE2L1-GPX4 pathway

Updated

Abstract

N-acetyltransferase 10 (NAT10) may enhance the malignant behavior of clear cell renal cell carcinoma (ccRCC).

  • NAT10 is associated with high mortality rates in ccRCC and contributes to cancer progression.
  • The study observed that NAT10 can inhibit markers linked to a type of cell death known as .
  • NAT10 may influence ccRCC through the nuclear factor erythroid-2, like-1 ()-glutathione peroxidase-4 () signaling pathway.
  • Modulation of NAT10 could represent a new therapeutic target for treating ccRCC.

Simplified

Key figures

Figure 1
expression levels in normal versus tumor renal clear cell carcinoma tissues
Highlights higher NAT10 expression and lower survival in tumor tissues, spotlighting its potential role in cancer progression
peerj-13-20224-g001
  • Panels A, B, C
    and images show NAT10 expression (red) in normal and tumor tissues, with tumor tissues visibly having higher NAT10 signal; (green) and nuclei (blue) are also labeled
  • Panel D
    quantification shows higher relative NAT10 mRNA levels in tumor tissues compared to normal tissues
  • Panel E
    RT-PCR shows higher NAT10 mRNA levels in metastatic tumor tissues compared to non-metastatic tumor tissues
  • Panel F
    RT-PCR shows higher NAT10 mRNA levels in tumor tissues identified as NAT10 positive by immunohistochemistry compared to NAT10 negative tissues
  • Panel G
    Survival curve shows lower probability in patients with high NAT10 expression compared to low NAT10 expression
Figure 2
expression effects on proliferation, migration, and invasion in renal clear cell carcinoma cells
Highlights increased proliferation, migration, and invasion with higher NAT10 expression in renal carcinoma cells
peerj-13-20224-g002
  • Panel A
    Relative NAT10 mRNA levels measured by in different renal clear cell carcinoma cell lines
  • Panel B
    NAT10 expression silenced by in ACHN cells, showing reduced mRNA levels compared to control
  • Panel C
    NAT10 overexpressed () in Caki1 cells, showing increased mRNA levels compared to control
  • Panel D
    Cell proliferation of ACHN cells measured by after NAT10 silencing; shNAT10 group shows lower viability than control
  • Panel E
    Cell proliferation of Caki1 cells measured by CCK-8 assay after NAT10 overexpression; OE-NAT10 group shows higher viability than control
  • Panels F, G, H
    images and quantification of migration in ACHN and Caki1 cells; shNAT10 in ACHN shows larger blank area (less migration), OE-NAT10 in Caki1 shows smaller blank area (more migration)
  • Panels F, I, J
    images and quantification in ACHN and Caki1 cells; shNAT10 in ACHN shows lower absorbance (less invasion), OE-NAT10 in Caki1 shows higher absorbance (more invasion)
Figure 3
High vs low expression in : gene differences and related pathway enrichment
Highlights key gene expression changes and enriched pathways linked to NAT10 that relate to in ccRCC.
peerj-13-20224-g003
  • Panel A
    Volcano plot of differentially expressed genes () between high and low NAT10 expression in ccRCC; red dots indicate significantly up-regulated genes, blue dots indicate significantly down-regulated genes, and gray dots are not significant.
  • Panel B
    Heat map of 177 overlapping genes between NAT10-related DEGs and ferroptosis-related down-regulated genes in ccRCC; red indicates high expression and blue indicates low expression across samples.
  • Panel C
    Bubble map of for DEGs in ccRCC; point size shows gene count and color indicates adjusted p-values, highlighting pathways like glutathione metabolism, oxidative stress response, antioxidant pathways, and ferroptosis signaling.
Figure 4
Normal vs tumor tissues and modified cells: expression of -related proteins and iron, , levels
Highlights higher expression and iron-related changes linked to in tumor versus normal tissues
peerj-13-20224-g004
  • Panels A-C
    shows GPX4 and protein expression; tumor tissues have higher GPX4 and NFE2L1 levels than normal tissues
  • Panels D-E
    measures mRNA levels of GPX4 and NFE2L1; tumor tissues show increased expression compared to normal tissues
  • Panels F-I
    shows ferroptosis marker proteins CHAC1, PTGS2, and SLC7A11; CHAC1 and PTGS2 are lower, SLC7A11 is higher in tumor tissues versus normal
  • Panels J-K
    Iron levels measured in ACHN and Caki1 cells; iron decreases after NAT10 silencing in ACHN and increases after NAT10 overexpression in Caki1
  • Panels L-M
    MDA levels measured in ACHN and Caki1 cells; MDA decreases after NAT10 silencing in ACHN and increases after NAT10 overexpression in Caki1
  • Panels N-Q
    ROS levels measured by fluorescence in ACHN and Caki1 cells; ROS decreases after NAT10 silencing in ACHN and increases after NAT10 overexpression in Caki1
Figure 5
silencing vs overexpression: expression levels of and in renal cancer cells
Highlights how NAT10 expression levels visibly influence key proteins linked to regulation in renal cancer cells
peerj-13-20224-g005
  • Panel A
    measurement of GPX4 and NFE2L1 mRNA levels in ACHN cells after NAT10 silencing; both markers show reduced expression compared to control
  • Panel B
    RT-PCR measurement of GPX4 and NFE2L1 mRNA levels in Caki1 cells after NAT10 overexpression; both markers show increased expression compared to control
  • Panels C and D
    Western blot and quantification of GPX4 and NFE2L1 protein levels in Caki1 cells; protein levels appear lower with NAT10 silencing and higher with NAT10 overexpression compared to control
  • Panels E and F
    images and quantification of GPX4 and NFE2L1 in Caki1 cells; fluorescence intensity and positive cell numbers appear reduced with NAT10 silencing and increased with NAT10 overexpression
1 / 5

Full Text

What this is

  • This research investigates the role of N-acetyltransferase 10 (NAT10) in clear cell renal cell carcinoma (ccRCC).
  • ccRCC is a common and aggressive kidney cancer with poor prognosis and limited treatment options.
  • NAT10 is shown to inhibit , a form of cell death, thereby promoting tumor progression through the - signaling pathway.

Essence

  • NAT10 enhances the malignant behavior of ccRCC by inhibiting through the - signaling pathway, suggesting its potential as a therapeutic target.

Key takeaways

  • NAT10 is overexpressed in ccRCC tissues, correlating with poor patient prognosis. Elevated NAT10 levels are associated with increased tumor malignancy.
  • NAT10 promotes cell proliferation, migration, and invasion in ccRCC. Overexpression of NAT10 significantly enhances these malignant behaviors.
  • NAT10 inhibits by upregulating and , which are critical for cell survival, thereby facilitating ccRCC progression.

Caveats

  • The study is limited by a small sample size of 30 paired ccRCC and normal tissues, which may affect the robustness of the findings.
  • Clinical data lacked detailed stratification, such as VHL mutation status, which could influence iron metabolism and in ccRCC.

Definitions

  • ferroptosis: An iron-dependent form of programmed cell death characterized by lipid peroxidation and distinct from apoptosis and necrosis.
  • NFE2L1: A transcription factor that regulates antioxidant responses and protects against ferroptosis by promoting GPX4 expression.
  • GPX4: An enzyme that reduces lipid peroxides, preventing ferroptosis and promoting cell survival.

Simplified

Funding

Competing interests

The authors declare there are no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free